Medherant Ltd, a UK spin-out which is developing a transdermal drug delivery patch technology, has appointed Ken Cunningham as chairman of its board of directors. Dr Cunningham is a former chief executive of SkyePharma Plc, which was acquired by Vectura Group Plc in 2016. He is currently chairman of Abzena Plc as well as a non-executive director of Verona Pharma Plc.
He holds a medical degree from St Mary’s Imperial College London.
Medherant announced the appointment on 6 February 2017.
Copyright 2017 Evernow Publishing Ltd